Enovis (FRA:C520) Total Equity: €1,280 Mil (As of Mar. 2026)


FRA:C520 Enovis Corp FRA:C520
64 GF Score
Price €21.80
GF Value €42.46
! 6 Warning Signs
View Full Analysis

What is Enovis Total Equity?

Enovis FRA:C520 +6.86% 64 Total Equity is €1,280 Mil as of Mar. 2026. GuruFocus rates FRA:C520 with a GF Score™ of 64/100 and a GF Value™ of €42.46. The stock has 6 warning signs investors should review.

Enovis's total equity for the quarter that ended in Mar. 2026 was €1,280 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Enovis Total Equity Historical Data

* Premium members only.

The historical data trend for Enovis's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enovis Total Equity Chart

Enovis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,125.37 3,256.61 3,136.78 2,448.93 1,274.08

Enovis Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,423.70 2,237.69 1,724.17 1,274.08 1,279.76
FRA:C520
64GF Score
Enovis Corp FRA:C520
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enovis Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Enovis's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=3274.865-2000.781
=1,274

Enovis's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=3314.901-2035.141
=1,280

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €1,280 Mil mean?
Enovis (FRA:C520) has a Total Equity of €1,280 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Enovis and its competitors.
Is Enovis' Total Equity too high?
Enovis' current Total Equity is €1,280 Mil. Overall, Enovis has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Enovis' Total Equity compare to INSP and PRCT?
Enovis' Total Equity of €1,280 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Enovis and its competitors. Enovis's current Total Equity is €1,280 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enovis stock overvalued right now?
Enovis (FRA:C520) has a current Total Equity of €1,280 Mil. The stock's GF Value™ is €42.46, compared to a current price of €21.80 — trading 48.7% below its estimated fair value. The current Total Equity is €1,280 Mil. Enovis' overall GF Score™ is 64/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Enovis (FRA:C520), the current Total Equity is €1,280 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enovis (FRA:C520) Overvalued in 2026?

Based on GuruFocus' analysis, Enovis stock appears to be undervalued. The current stock price of €21.80 is trading 48.7% below its estimated GF Value™ of €42.46.

Key valuation signals for FRA:C520:

  • Total Equity: €1,280 Mil
  • GF Value™: €42.46 vs. price of €21.80 (48.7% below fair value)
  • GF Score™: 64/100 with 6 warning signs

No single metric tells the full story. See the FRA:C520 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Enovis Business Description

Address 2711 Centerville Road, Suite 400, Wilmington, DE, USA, 19808
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.
64GF Score

Get the complete analysis for FRA:C520

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€21.80
Price
€42.46
GF Value